Trifluoperazine
From Ganfyd
rINN: Trifluoperazine
Other Names
Stelazine®
Pharmacological Information
Pharmacology Images
Trifluoperazine in the:
BNF-registration required
BNF for children-registration required
Relevant Clinical Literature
Systematic reviews from Pubmed
Other Literature
Please read pharmacological data limitations
Contents |
Introduction
Clinical Use
Indications
Administration
Oral in adults 2mg in anxiety, 5mg bd or 10mg od increasing in psychosis
Clinical Issues
Side effects
- Blood dyscrasias especially at more than 6mg daily
- Anorexia
Class Clinical Issues
Contra-indications
Dementia is probably a contraindication for any antipsychotic (fair evidence for increased mortality in long term use) and has an interesting medicolegal potential as it is unclear if following recent changes in datasheets (SPCs) and warnings from the regulatory authorities (eg FDA) any manufacturer will share liability for out of licence use (off license) use in newly commenced patients. In the UK an urgent review is taking place as of 2008.
- CNS depression
- Phaeochromocytoma
Cautions
- Driving
- Breast feeding and pregnancy (many contra-indicated or best avoided)
- Withdrawal should be gradual
- Hepatic impairment
- Renal impairment
- Cardiovascular disease
- Parkinsonism
- Epilepsy
- Blood dyscrasias
- Depression
- Myasthenia gravis
- Associated with increased venous thromboembolic disease
Side-effects
- Postural hypotension
- Parkinsonism
- Dystonia
- Akathisia
- Tardive dyskinesia
- Jaundice
- Drowsiness
- Apathy
- Excitement
- Neuroleptic malignant syndrome
- Insomia
- Anticholinergic side-effects
- Blood dyscrasias
- Hyperprolactinaemia
- Weight gain
- Skin pigmentation (purple)
- Photosensitisation at higher doses
- Cataracts & corneal opacities
